Febuxostat

Drug Profile

Febuxostat

Alternative Names: Adenuric; Feburic; TEI-6720; TMX 67XR; TMX-67; Uloric

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Teijin Pharma
  • Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda; Takeda Pharmaceuticals USA; Teijin Pharma
  • Class Antigouts; Carboxylic acids; Nitriles; Phenyl ethers; Small molecules; Thiazoles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout; Hyperuricaemia
  • Registered Tumour lysis syndrome
  • Phase II Hypertension
  • Suspended Angina pectoris

Most Recent Events

  • 02 Jan 2017 Phase-II clinical trials in Tumour lysis syndrome (Prevention, In children, In adults, In adolescents) in Spain (PO) (EudraCT2016-001445-61)
  • 13 Nov 2016 Efficacy data from a phase II trial in Gout released by Takeda
  • 11 Nov 2016 Efficacy data from a phase II trial in Gout presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top